Vonoprazan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Vonoprazan is a potassium-competitive acid blocker used in the treatment of erosive diseases of the digestive tract, including reflux esophagitis and duodenal ulcers.

Generic Name
Vonoprazan
DrugBank Accession Number
DB11739
Background

Vonoprazan has been used in trials studying the treatment of Erosive Esophagitis.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 345.39
Monoisotopic: 345.094726104
Chemical Formula
C17H16FN3O2S
Synonyms
  • Vonoprazan

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Alendronic acidThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Vonoprazan.
AmphetamineVonoprazan can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
AmprenavirVonoprazan can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
AsunaprevirVonoprazan can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy.
AtazanavirVonoprazan can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
BelumosudilThe serum concentration of Belumosudil can be decreased when it is combined with Vonoprazan.
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Vonoprazan.
BosutinibVonoprazan can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
BudesonideVonoprazan can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CaptoprilVonoprazan can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more

Categories

ATC Codes
A02BD14 — Vonoprazan, amoxicillin and clarithromycinA02BD15 — Vonoprazan, amoxicillin and metronidazoleA02BC08 — Vonoprazan
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylpyrroles. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrole ring through a CC or CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrroles
Sub Class
Substituted pyrroles
Direct Parent
Phenylpyrroles
Alternative Parents
Pyridinesulfonamides / Fluorobenzenes / Aralkylamines / Aryl fluorides / Sulfonyls / Organosulfonic acids and derivatives / Heteroaromatic compounds / Dialkylamines / Azacyclic compounds / Organofluorides
show 2 more
Substituents
2-phenylpyrrole / Amine / Aralkylamine / Aromatic heteromonocyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenoid / Fluorobenzene / Halobenzene
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
1R5L3J156G
CAS number
881681-00-1
InChI Key
BFDBKMOZYNOTPK-UHFFFAOYSA-N
InChI
InChI=1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3
IUPAC Name
{[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl]methyl}(methyl)amine
SMILES
CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1

References

General References
  1. FDA Thailand Product Information: Vocinti (vonoprazan fumarate) oral tablets [Link]
PubChem Compound
15981397
PubChem Substance
347828097
ChemSpider
13112797
BindingDB
394392
ChEBI
136048
ChEMBL
CHEMBL2079130
ZINC
ZINC000034842823
PDBe Ligand
HKT
Wikipedia
Vonoprazan
PDB Entries
5ylu

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentErosive Esophagitis1
4CompletedTreatmentReflux Esophagitis (RE)1
4Not Yet RecruitingPreventionAcute Coronary Syndrome (ACS) / Helicobacter Pylori Infection1
4RecruitingTreatmentGastro-esophageal Reflux Disease (GERD) / Gastroesophageal Reflux1
4RecruitingTreatmentHelicobacter Pylori Infection3
3Active Not RecruitingTreatmentErosive Esophagitis1
3CompletedTreatmentDuodenal Ulcer1
3CompletedTreatmentErosive Esophagitis2
3CompletedTreatmentGastric Ulcer1
3CompletedTreatmentGastritis Associated With Helicobacter Pylori1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, film coatedOral
Tablet, film coatedOral10 mg
Tablet, film coatedOral20 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.049 mg/mLALOGPS
logP1.78ALOGPS
logP2.03ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)9.01ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.99 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity90.16 m3·mol-1ChemAxon
Polarizability34.23 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 20:43 / Updated on May 07, 2021 21:07